Healthcare

Kailera Therapeutics is a small biotechnology company targeting obesity and related metabolic diseases, an area drawing intense industry attention. Its appeal comes from focused pipeline exposure, strong R&D commitment, and a low-debt balance sheet that supports development flexibility.

Kardigan is a clinical-stage cardiovascular biotech aiming to address major heart-rhythm needs, with attention centered on its atrial fibrillation program. The company offers focused exposure to a large market, with future value tied mainly to trial progress and execution.

Innoviva blends high-margin respiratory royalties with a growing portfolio of owned pharmaceutical assets. Strong cash generation, high returns on capital, and a much lower valuation than sector peers make its evolving healthcare model worth a closer look.

Inhibrx Biosciences is a focused biotech centered on antibody medicines for cancer and rare diseases. Its sharper post-transaction structure and strong stock momentum have increased attention, with future value now tied closely to upcoming clinical progress.

Healthcare Services Group provides outsourced housekeeping and dietary services to long-term care facilities. The recent picture is shaped by stronger margins, rising free cash flow, and very low debt, making this a notable recovery case within a steady healthcare niche.

Green Thumb Industries is one of the more profitable U.S. cannabis operators, combining branded products, owned dispensaries, and rising free cash flow. The business has slowed from its early growth phase, but its operating discipline and margins make it stand out.